136 related articles for article (PubMed ID: 32916243)
1. The pre membrane and envelope protein is the crucial virulence determinant of Japanese encephalitis virus.
Leng SL; Huang R; Feng YN; Peng LJ; Yang J; Li YH
Microb Pathog; 2020 Nov; 148():104492. PubMed ID: 32916243
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for attenuation of neurovirulence of a yellow fever Virus/Japanese encephalitis virus chimera vaccine (ChimeriVax-JE).
Arroyo J; Guirakhoo F; Fenner S; Zhang ZX; Monath TP; Chambers TJ
J Virol; 2001 Jan; 75(2):934-42. PubMed ID: 11134306
[TBL] [Abstract][Full Text] [Related]
3. Genetic Determinants of Japanese Encephalitis Virus Vaccine Strain SA14-14-2 That Govern Attenuation of Virulence in Mice.
Gromowski GD; Firestone CY; Whitehead SS
J Virol; 2015 Jun; 89(12):6328-37. PubMed ID: 25855730
[TBL] [Abstract][Full Text] [Related]
4. A molecularly cloned, live-attenuated japanese encephalitis vaccine SA14-14-2 virus: a conserved single amino acid in the ij Hairpin of the Viral E glycoprotein determines neurovirulence in mice.
Yun SI; Song BH; Kim JK; Yun GN; Lee EY; Li L; Kuhn RJ; Rossmann MG; Morrey JD; Lee YM
PLoS Pathog; 2014 Jul; 10(7):e1004290. PubMed ID: 25077483
[TBL] [Abstract][Full Text] [Related]
5. Envelope Protein Mutations L107F and E138K Are Important for Neurovirulence Attenuation for Japanese Encephalitis Virus SA14-14-2 Strain.
Yang J; Yang H; Li Z; Wang W; Lin H; Liu L; Ni Q; Liu X; Zeng X; Wu Y; Li Y
Viruses; 2017 Jan; 9(1):. PubMed ID: 28117725
[TBL] [Abstract][Full Text] [Related]
6. Chimeric Japanese Encephalitis Virus SA14/SA14-14-2 Was Virulence Attenuated and Protected the Challenge of Wild-Type Strain SA14.
Huang R; Leng S; Feng Y; Tang L; Yuan L; Yang J
Can J Infect Dis Med Microbiol; 2019; 2019():9179308. PubMed ID: 30944684
[TBL] [Abstract][Full Text] [Related]
7. A novel amino acid site closely associated with the neurovirulence of live, attenuated Japanese encephalitis vaccine (SA14-14-2 strain).
Yang H; Fan F; Liu L; Liu J; Sun Y; Xie A; Shi X; Liu L; Yu Y; Li Y; Ge Y; Zeng X; Yang H
Vaccine; 2020 Mar; 38(11):2636-2642. PubMed ID: 32044162
[TBL] [Abstract][Full Text] [Related]
8. Comparison of the live-attenuated Japanese encephalitis vaccine SA14-14-2 strain with its pre-attenuated virulent parent SA14 strain: similarities and differences in vitro and in vivo.
Yun SI; Song BH; Polejaeva IA; Davies CJ; White KL; Lee YM
J Gen Virol; 2016 Oct; 97(10):2575-2591. PubMed ID: 27498826
[TBL] [Abstract][Full Text] [Related]
9. Acidity/Alkalinity of Japanese Encephalitis Virus E Protein Residue 138 Alters Neurovirulence in Mice.
Zheng X; Zheng H; Tong W; Li G; Wang T; Li L; Gao F; Shan T; Yu H; Zhou Y; Qiu Y; Ma Z; Tong G
J Virol; 2018 Nov; 92(22):. PubMed ID: 30158291
[TBL] [Abstract][Full Text] [Related]
10. Envelope protein gene based molecular characterization of Japanese encephalitis virus clinical isolates from West Bengal, India: a comparative approach with respect to SA14-14-2 live attenuated vaccine strain.
Sarkar A; Banik A; Pathak BK; Mukhopadhyay SK; Chatterjee S
BMC Infect Dis; 2013 Aug; 13():368. PubMed ID: 23927571
[TBL] [Abstract][Full Text] [Related]
11. Molecular basis of attenuation of neurovirulence of wild-type Japanese encephalitis virus strain SA14.
Ni H; Chang GJ; Xie H; Trent DW; Barrett AD
J Gen Virol; 1995 Feb; 76 ( Pt 2)():409-13. PubMed ID: 7844560
[TBL] [Abstract][Full Text] [Related]
12. Phenotypic and genotypic characteristics of Japanese encephalitis attenuated live vaccine virus SA14-14-2 and their stabilities.
Yu Y
Vaccine; 2010 May; 28(21):3635-41. PubMed ID: 20226891
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cytopathic effect of Japanese encephalitis virus strain SA14-14-2: Probable association of mutation in amino acid of its envelope protein.
Nath B; Gupta A; Khan SA; Kumar S
Microb Pathog; 2017 Oct; 111():187-192. PubMed ID: 28867626
[TBL] [Abstract][Full Text] [Related]
14. [Construction of infectious Japanese encephalitis virus clone based on the cDNA template of the attenuated live vaccine production strain SA14-14-2].
Zeng M; Jia LL; Yu YX; Dong GM; Liu WX; Wang ZW; Li DF
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2005 Mar; 19(1):9-11. PubMed ID: 16201461
[TBL] [Abstract][Full Text] [Related]
15. The A66G back mutation in NS2A of JEV SA14-14-2 strain contributes to production of NS1' protein and the secreted NS1' can be used for diagnostic biomarker for virulent virus infection.
Wang J; Li X; Gu J; Fan Y; Zhao P; Cao R; Chen P
Infect Genet Evol; 2015 Dec; 36():116-125. PubMed ID: 26384477
[TBL] [Abstract][Full Text] [Related]
16. Increased Cleavage of Japanese Encephalitis Virus prM Protein Promotes Viral Replication but Attenuates Virulence.
Xiong J; Yan M; Zhu S; Zheng B; Wei N; Yang L; Si Y; Cao S; Ye J
Microbiol Spectr; 2022 Jun; 10(3):e0141722. PubMed ID: 35695552
[TBL] [Abstract][Full Text] [Related]
17. Characterization of live-attenuated Japanese encephalitis vaccine virus SA14-14-2.
Yang D; Li XF; Ye Q; Wang HJ; Deng YQ; Zhu SY; Zhang Y; Li SH; Qin CF
Vaccine; 2014 May; 32(23):2675-81. PubMed ID: 24709585
[TBL] [Abstract][Full Text] [Related]
18. Immune responses and protective effects against Japanese encephalitis induced by a DNA vaccine encoding the prM/E proteins of the attenuated SA14-14-2 strain.
Zheng X; Yu X; Wang Y; Cui M; Wang R; Yin C
Infect Genet Evol; 2020 Nov; 85():104443. PubMed ID: 32619637
[TBL] [Abstract][Full Text] [Related]
19. Genotype-specific neutralization determinants in envelope protein: implications for the improvement of Japanese encephalitis vaccine.
Ye Q; Xu YP; Zhang Y; Li XF; Wang HJ; Liu ZY; Li SH; Liu L; Zhao H; Nian QG; Deng YQ; Qin ED; Qin CF
J Gen Virol; 2015 Aug; 96(8):2165-2175. PubMed ID: 25908779
[TBL] [Abstract][Full Text] [Related]
20. Recombinant, chimaeric live, attenuated vaccine (ChimeriVax) incorporating the envelope genes of Japanese encephalitis (SA14-14-2) virus and the capsid and nonstructural genes of yellow fever (17D) virus is safe, immunogenic and protective in non-human primates.
Monath TP; Soike K; Levenbook I; Zhang ZX; Arroyo J; Delagrave S; Myers G; Barrett AD; Shope RE; Ratterree M; Chambers TJ; Guirakhoo F
Vaccine; 1999 Apr; 17(15-16):1869-82. PubMed ID: 10217584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
